亚洲100强：2026年生物制药未来展望（英）

UnfoldingThe Future Of Foreword Contents While the biopharma industry’s attentionglobally this year has been mainly directedtowards the US and what policies PresidentDonald Trump may, or may not, implement, While the precise shape of policy changesunder the country’s new president wasstill unclear at the time of writing but the Brought to you by Ian HaydockEditor-in-Chief,APAC Japan meanwhile has been most notablefor other forms of transactions – non-pharmaprivate equity and investment firms moving The headline theme since last year’s ScripAsia 100 has undoubtedly been China’scontinued rapid emergence as a global R&Dpowerhouse. As of early 2025, close to 1,500new drugs were in Chinese development, Bain Capital’s early Februaryannouncement it would acquire MitsubishiTanabe Pharma for around $3.4bn wasfollowed by Blackstone’s agreement to acquire60% of leading contract research organization Sponsored by The top two in terms of number of NASlaunches were both Chinese companies, whichalso dominated the top 10 ranking in Citeline’s The pace of deals under which majormultinationals licensed either global orselected rights to assets originated by Chinesecompanies has accelerated so far in 2025,with one of the biggest alliances including Across in India, perhaps the biggest topicpreoccupying the industry there this year hasbeen how the huge US generics market willbe influenced by changing policies under the Indian firms too crossed a bridge in termsof innovation, with the deal between Glenmarkand AbbVie for a first-in-class trispecificantibody for multiple myeloma valued at close ASIA TEAM SCRIP ASIA 100 EDITORSAndrea CharlesIzabela ChmielewskaMeredith Landry CUSTOMER SERVICES Anju GhangurdeXu HuVibha RaviJung Won Shin Tel:UK & Europe: +44 203 480 7600US Toll-free: +1 888 670 8900 But the story was not entirely about China.The Citeline data also showed South Koreawas the third most common base for allcompanies globally reporting active R&D.Indeed, Korean companies struck several This introduction touches on just some of thestand-out trends of the past year. We hope thecarefully selected data, articles and analyses inthis year’s Scrip Asia 100 will give you deeperinsights, helped by the expertise and contacts URL:insights.citeline.com/scripTo subscribe, visithttps://www.citeline.com/en/app-insights-trial EDITORS-IN-CHIEF Ian Haydock (Asia)Nielsen Hobbs (Regulatory)Eleanor Malone (Commercial) DATA, DESIGN &PRODUCTION Edwin ElmhirstNancy Pham To advertise, contactchristopher.keeling@citeline.com EXECUTIVE EDITORSCOMMERCIAL Mary Jo Laffler (US)Alexandra Shimmings (Europe) All stock images in thispublication are courtesy ofwww.shutterstock.com Scripis published by Pharma Intelligence UKLimited (Citeline). © 2025 Pharma IntelligenceUK Limited (Citeline), a Norstella company: EXECUTIVE EDITORSREGULATORY Neena Brizmohun (Europe)Derrick Gingery (US) this increasingly competitive landscape. For biotechs inChina partnering with a global, rather than local, CRO isessential to attract foreign pharma partners, out-licensingopportunities, or venture capital (VC) funding. Potentialpartners and funders will expect to see data from studiesoutside China. Partnering with the right global CRO ensuresbiotechs can satisfy those funding requirements. The right Center for Drug Evaluation (CDE) shows that the therapeuticareas where innovative treatments are being investigatedfocus on oncology, dermatology and ENT, endocrinology, Enabling Innovation: How China-Based Biotechs CNS, and respiratory treatments.3The Chinese governmenthas introduced incentives to support pediatric and raredisease drug development, resulting in the launch ofapproximately 114 pediatric studies and 121 rare diseasestudies in 2024. Oncology and immunology remain key ICON BIOTECH: A CRO PARTNER IN CHINA THE SECRETS TO SUCCESS: SECURING FUNDING, ICON Biotech, the world’s largest dedicated biotechCRO, works with small, emerging, and midsize biopharmacustomers. We offer the resources, services, and globalreach of a global biotech CRO, matched with therapeuticallyaligned single points of contact. Connected with officesin more than 50 countries and 95 locations – includingin China’s four pharmaceutical hubs – ICON Biotechsupports ambitious biotech and pharma companiesacross the globe. By leveraging the benefits of thebroader ICON organization, our customers can accessextensive experience across a range of therapeutic areas.ICON’s presence in China dates to 1997, giving us a deepunderstanding of the local challenges and the global Success cannot be achieved without overcoming somedifficulties. Securing sustainable funding is a universalchallenge for biotechs, no matter where they are located;China is no exception. In the current macro-economiccontext, most Chinese government funding is linked tothe early stages of trials, and biotechs often seek externalfunding to support later study phases. While some biotechshave existing commercial